Zenas BioPharma, Inc. (ZBIO)

Price$32.88Cached quoteAs of 2026-09-05 06:53 UTC

AI: Fair-priced

Price checkThe valuation already prices in meaningful obexelimab success while leaving some upside for broader pipeline wins.

Zenas BioPharma, Inc. is confirmed as ZBIO on the Nasdaq Global Select Market. Recent market data place its equity value around $2.2 billion, while June cash, cash equivalents and investments were $673.9 million. The market is therefore assigning substantial value to the drug pipeline beyond cash. Traditional P/E is not useful because Zenas remains loss-making and has no product-sales revenue. This is not a normal cyclical business: valuation moves mainly with clinical, regulatory and biotech-funding cycles rather than economic demand.

Big pictureCash runway is strong, but losses, debt claims, royalties, and equity issuance materially temper the balance-sheet cushion.

Zenas is still pre-commercial: Q2 revenue was $1.0 million of license revenue, the quarterly net loss was $111.5 million, and first-half operating cash use was $132.4 million. At June 30, cash and investments totaled $673.9 million. Outstanding financing included a $75 million secured term loan and $230 million of convertible-note principal. Management projects funding into 2029, while some runway assumptions include milestone and debt proceeds tied to FDA approval. After quarter-end, another $48.7 million was raised through the ATM share program, improving liquidity but adding dilution.

Business strengthLead-drug evidence is strong, but economics remain unproven and commercialization carries meaningful licensing and royalty costs.

Obexelimab’s Phase 3 INDIGO study reduced IgG4-RD flare risk by 56% versus placebo and met all key secondary endpoints; the FDA later accepted the BLA and set a May 27, 2027 target action date. That materially lowers clinical risk for the lead indication. The broader portfolio adds upside through SLE, orelabrutinib and ZB021. Still, Zenas has no product-sales history, commercialization costs are rising, and obexelimab carries Xencor milestones and mid-single-digit to mid-teens royalties plus a 5.5% Royalty Pharma participation, limiting economics if sales succeed.

What could change the storyUpcoming SLE data and the FDA decision can sharply expand or shrink the value investors assign the pipeline.

Bull case: SunStone reports convincing SLE efficacy in late 2026, ZB021 shows encouraging initial activity, the FDA approves obexelimab on schedule, and launch uptake supports a durable autoimmune franchise without major additional equity needs. Bear case: SLE or early ZB021 data disappoint, regulatory review slips, IgG4-RD adoption is slower than expected, or trial and launch spending stays high enough to require repeated ATM sales. The recent financing lowers near-term funding risk, but future success is shared with lenders, noteholders, licensors and royalty holders.

AI: News

FDA Review Clock SetFDA acceptance moved obexelimab into formal review and established a clear regulatory decision date.

On August 13, Zenas said the FDA had accepted the obexelimab BLA for IgG4-related disease and assigned a May 27, 2027 PDUFA target date. Acceptance does not guarantee approval, but it confirms the application cleared the filing review and begins the formal regulatory clock. Zenas also reiterated plans for a European marketing application in the second half of 2026, expanding the potential commercial path beyond the United States.

Q2 Liquidity Remains StrongSecond-quarter results showed ample liquidity alongside sharply higher losses and continued reliance on external financing.

Zenas reported $673.9 million of cash, cash equivalents and investments at June 30, alongside a $111.5 million quarterly net loss and $62.9 million of Q2 research and development expense. The company expects its resources to fund operations into 2029 under stated assumptions. It also disclosed additional ATM share sales after quarter-end, reinforcing cash durability while increasing the number of shares over which future value is spread.

INDIGO Results PublishedFull INDIGO results strengthened the lead program by confirming efficacy, steroid sparing, and comparable safety.

On June 2, Zenas released detailed Phase 3 INDIGO results for obexelimab in IgG4-related disease, alongside presentation at EULAR and publication in the New England Journal of Medicine. The study showed a 56% reduction in flare risk versus placebo, met all key secondary endpoints, and reduced glucocorticoid exposure and related toxicity. The company said safety was comparable with placebo, supporting the regulatory submission made in May.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$10.0M	$5.0M	$50.0M	$0
Research & development	$168.1M	$139.1M	$60.0M	$61.7M
Operating expenses	$393.1M	$168.9M	$87.1M	$75.2M
Operating income	−$383.1M	−$163.9M	−$37.1M	−$75.2M
Operating margin	−3,830.57%	−3,277.76%	−74.29%	—
EBITDA	−$383.0M	−$163.8M	−$37.0M	−$75.1M
EBITDA margin	−3,830.01%	−3,275.02%	−74.07%	—
Net income	−$377.7M	−$157.0M	−$37.1M	−$119.3M
Net profit margin	−3,777.37%	−3,139.76%	−74.25%	—
Basic EPSper basic share	-$8.44	-$11.89	-$24.25	-$9.26
Diluted EPSper diluted share	-$8.44	-$11.89	-$24.25	-$9.26

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

15.01%of listed shares

FMR LLC9.51M shares · Jun 30, 2026

View holders

Top 20 reported holders of ZBIO
Holder	% owned
FMR LLC	15.01%9.51M shares
SR ONE CAPITAL MANAGEMENT, LLC / George Simeon	≈7.95%5.04M shares
SR One Capital Management, LP	7.95%5.04M shares
InnoCare Pharma Inc.	≈7.90%5M shares
NEA Management Company, LLC	6.35%4.02M shares
ENAVATE SCIENCES GP, LLC	6.19%3.92M shares
Nunn Jason Raleigh	≈4.93%3.12M shares
FEDERATED HERMES, INC.	4.92%3.12M shares
BlackRock, Inc.	4.24%2.69M shares
ENRIGHT PATRICK G	≈4.14%2.62M shares
Capital International Investors	3.95%2.5M shares
Polar Capital Holdings Plc	3.81%2.41M shares
Royalty Pharma Sub-Manager, LLC	3.77%2.39M shares
Fairmount Funds Management LLC	3.72%2.36M shares
MOULDER LEON O JR	≈3.64%2.31M shares
STATE STREET CORP	3.25%2.06M shares
NVP ASSOCIATES, LLC	2.90%1.84M shares
WELLINGTON MANAGEMENT GROUP LLP	2.52%1.59M shares
VANGUARD CAPITAL MANAGEMENT LLC	2.14%1.35M shares
BANK OF AMERICA CORP /DE/	1.94%1.23M shares

Percentages use 63.33M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Reported positions exceed 100% in total, so the circle shows the selected holder only.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys47$118.28M disclosed value

Sells (SEC code S)0$0.00 disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
May 18, 2026Form 4	MOULDER LEON O JRChief Executive Officer	BuyCommon Stock · indirect	60.0K	$16.88	$1.01M	96.9K
Apr 29, 2026Form 4	MOULDER LEON O JRChief Executive Officer	BuyCommon Stock · indirect	35.0K	$17.62	$616.7K	1.79M
Apr 28, 2026Form 4	MOULDER LEON O JRChief Executive Officer	BuyCommon Stock · indirect	25.0K	$18.02	$450.5K	1.75M
Mar 31, 2026Form 4	Lu HongboDirector	BuyCommon Stock · indirect	3.8K	$18.63	$70.2K	426.7K
Mar 31, 2026Form 4	Kiselak Tomas +3Director	BuyCommon Stock · indirect	150.0K	$20.00	$3.00M	2.36M

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about ZBIO yet. Start the conversation.

Write the first post

Zenas BioPharma, Inc. (ZBIO)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.